Vaccinex, Inc. (VCNX) stock
VCNXOTCPharmaceutical PreparationsFiscal year ends December 31
Financials through Q4 FY2024, quarter ended Dec 31, 2024Last filing: 10-K on Apr 15, 2025
$1.00−0.01 (-0.99%)
Close on Oct 19, 2026Market cap $3.22MP/E –Yield –
Vaccinex EPS
Diluted earnings per share is net income divided by the share count including options and convertible securities.
Vaccinex's EPS for the twelve months ending Dec 31, 2024 was -$8.88. For fiscal 2024 it was -$8.88. The highest annual figure on record is -$8.88 in fiscal 2024.
Annual eps
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | -$8.88 | – |
| FY2023 | Dec 31, 2023 | -$43.68 | – |
| FY2022 | Dec 31, 2022 | -$98.05 | – |
| FY2021 | Dec 31, 2021 | -$163.80 | – |
| FY2020 | Dec 31, 2020 | -$323.40 | – |
| FY2019 | Dec 31, 2019 | -$518.70 | – |
| FY2018 | Dec 31, 2018 | -$1186.50 | – |
| FY2017 | Dec 31, 2017 | -$4179.00 | – |
Quarterly eps
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2024 | Dec 31, 2024 | -$1.05 | – |
| Q3 FY2024 | Sep 30, 2024 | -$2.83 | – |
| Q2 FY2024 | Jun 30, 2024 | -$3.10 | – |
| Q1 FY2024 | Mar 31, 2024 | -$2.94 | – |
| Q3 FY2023 | Sep 30, 2023 | -$15.25 | – |
| Q2 FY2023 | Jun 30, 2023 | -$24.54 | – |
| Q1 FY2023 | Mar 31, 2023 | -$20.89 | – |
| Q4 FY2022 | Dec 31, 2022 | -$23.35 | – |
| Q3 FY2022 | Sep 30, 2022 | -$23.38 | – |
| Q2 FY2022 | Jun 30, 2022 | -$27.30 | – |
| Q1 FY2022 | Mar 31, 2022 | -$25.20 | – |
| Q4 FY2021 | Dec 31, 2021 | -$31.57 | – |
| Q3 FY2021 | Sep 30, 2021 | -$35.70 | – |
| Q2 FY2021 | Jun 30, 2021 | -$44.10 | – |
| Q1 FY2021 | Mar 31, 2021 | -$54.60 | – |
| Q4 FY2020 | Dec 31, 2020 | -$60.46 | – |
| Q3 FY2020 | Sep 30, 2020 | -$92.40 | – |
| Q2 FY2020 | Jun 30, 2020 | -$81.90 | – |
| Q1 FY2020 | Mar 31, 2020 | -$94.50 | – |
| Q4 FY2019 | Dec 31, 2019 | -$89.86 | – |
| Q3 FY2019 | Sep 30, 2019 | -$117.60 | – |
| Q2 FY2019 | Jun 30, 2019 | -$161.70 | – |
| Q1 FY2019 | Mar 31, 2019 | -$165.90 | – |
| Q3 FY2018 | Sep 30, 2018 | -$195.30 | – |
| Q2 FY2018 | Jun 30, 2018 | -$1411.20 | – |
| Q1 FY2018 | Mar 31, 2018 | -$1497.30 | – |
| Q4 FY2017 | Dec 31, 2017 | -$493.33 | – |
| Q3 FY2017 | Sep 30, 2017 | -$1207.50 | – |
| Q2 FY2017 | Jun 30, 2017 | -$1081.50 | – |
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- R&D Expenses
- Gross Margin
- Operating Margin
- Profit Margin
- Total Debt
- Cash
- Total Assets
- Shares Outstanding
- Market Cap
- Enterprise Value
- PE Ratio
- Price to Sales Ratio
- Price to Book Ratio
- EV/EBITDA
- Price to Free Cash Flow
- All statistics
See a number that looks wrong?